NXTC: Rounding Bottom detected on 21 Oct 2026

NXTC is forming a rounding bottom pattern with a structure score of 13.0, volume score of 12.0, and breakout score of 12.0 (overall pattern quality 68). The stock currently trades at $5.44, well below its 52-week high of $15.74 (down 65.4%), but 251% above its 52-week low of $1.55. Key support sits at $1.55, resistance at $11.20. RSI at 43.85 signals neutral momentum, while ATR of 0.80 (14.71% annualized volatility) reflects elevated price swings. A prior bull flag (pattern quality 30.9) and bullish pennant (27.0) suggest multiple bullish structures, though the rounding bottom's 67.65% win probability indicates moderate confirmation potential.

Nextcure is undergoing a merger with Avere Therapeutics, Inc., marking a fundamental transformation. The company reported Q2 2026 net loss of $14.9 million ($2.80 per share) with first-half 2026 net loss of $24.7 million and no product revenue. Critically, recurring losses and negative operating cash flows raise substantial doubt about continued going concern status. Nextcure is seeking court validation of a 1-for-12 reverse split, with a Delaware court hearing scheduled for November 6, 2026. Short interest surged 102.7% to 213,309 shares as of September 30, 2026, reflecting acute risk skepticism. Despite headwinds, HC Wainwright maintains a buy rating with consensus price target of $19.00.

A successful rounding bottom breakout would see NXTC close above the key resistance at $11.20, with the conservative measured move target at $5.76 representing modest upside from current $5.44. Volume confirmation is critical given current volume (82,116) is at 97% of 20-day average—breakout volume should exceed this baseline substantially. The 67.65% win probability suggests two-in-three patterns complete successfully. Pattern invalidation occurs if price closes below key support at $1.55, which would eliminate the rounding structure and signal continued deterioration. Beta of 1.87 indicates breakouts will amplify volatility—the measured move target of $5.76 represents just 5.9% upside, a modest risk-reward on a highly volatile biotech.

Substantial going concern doubt presents existential risk—the company expects $2.4 million restructuring charges through October 31, 2026, primarily severance and termination costs expected in Q3 2026. The pending 1-for-12 reverse split court hearing November 6, 2026 could alter capital structure and investor sentiment. Short interest doubled to 213,309 shares (6.7% of float) by September 30—any squeeze could prove volatile but unsustainable. StockInvest rates NXTC a Sell Candidate with technical score -4.90, with a sell signal since October 16, 2026, down 9.13%. High beta of 1.87 amplifies downside risk. The rounding bottom pattern forming amid merger uncertainty, cash burn, and elevated short covering pressure creates conflicting forces that challenge pattern reliability.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.